Reply to letter to editor: Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

Affiliations

¹ Division of Neonatology, Department of Pediatrics, King Abdullah bin Abdulaziz University Hospital, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. aarazak@kaauh.edu.sa.
² Division of Neonatology, Department of Pediatrics, Emirates Specialty Hospital, Dubai, United Arab Emirates.

Comment

Abdul Razak et al. J Perinatol. 2021 Nov.

. 2021 Nov;41(11):2692-2693.

doi: 10.1038/s41372-021-01127-1. Epub 2021 Jun 24.

¹ Division of Neonatology, Department of Pediatrics, King Abdullah bin Abdulaziz University Hospital, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia. aarazak@kaauh.edu.sa.
² Division of Neonatology, Department of Pediatrics, Emirates Specialty Hospital, Dubai, United Arab Emirates.

No abstract available

Comment on

Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis.
Rodriguez SH, Blair MP, Shapiro MJ, Berrocal AM, Ells AL, Hubbard GB 3rd, Martinez-Castellanos MA, Murray TG, Wu WC. Rodriguez SH, et al. J Perinatol. 2021 Sep;41(9):2377-2378. doi: 10.1038/s41372-021-01133-3. Epub 2021 Jun 30. J Perinatol. 2021. PMID: 34193960 No abstract available.

1. Kaushal M, Razak A, Patel W, Pullattayil AK, Kaushal A. Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2020. https://doi.org/10.1038/s41372-020-00884-9 .
1. Fan YY, Huang YS, Huang CY, Hsu JF, Shih CP, Hwang YS, et al. Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study. Ophthalmology. 2019;126:1567–77.
1. Arima M, Akiyama M, Fujiwara K, Mori Y, Inoue H, Seki E, et al. Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity. PLoS ONE. 2020;15:e0230678. - DOI
1. Rodriguez SH, Peyton C, Lewis K, Andrews B, Greenwald MJ, Schreiber MD, et al. Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019;50:337–43.
1. Anand N, Blair MP, Greenwald MJ, Rodriguez SH. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. J AAPOS. 2019;23:88E1–6. - DOI